The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Cilta-cel in earlier-line myeloma: insights into updated survival data
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the benefits of offering CAR T-cell therapy earlier in multiple myeloma treatment, citing the overall survival advantage of ciltacabtagene autoleucel (cilta-cel) from CARTITUDE-4 (NCT04181827) and long-term data from CARTITUDE-2 (NCT04133636). Prof. Einsele notes that these results are reassuring and suggest that earlier CAR T-cell therapy may benefit more patients with multiple myeloma. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It reassures us to really offer CAR T-cell therapy in early lines of therapy because we now have also the clear overall survival advantage for cilta-cel compared to conventional treatment that was tested in CARTITUDE-4. And in addition, and that was presented here at this meeting, is that we have now long-term data from CARTITUDE-2, which is also first to third line, first to third relapse following initial treatment for multiple myeloma...
It reassures us to really offer CAR T-cell therapy in early lines of therapy because we now have also the clear overall survival advantage for cilta-cel compared to conventional treatment that was tested in CARTITUDE-4. And in addition, and that was presented here at this meeting, is that we have now long-term data from CARTITUDE-2, which is also first to third line, first to third relapse following initial treatment for multiple myeloma. And this study showed a long-term disease-free survival at five years of 50%. So even increasing the data that we have from CARTITUDE-1, where we have 33% long-term disease-free survival without MRD, without a positive imaging. So potentially with earlier application, we’re also curing more patients with multiple myeloma. So clearly reassuring data.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
